After BioNTech SE and Pfizer, Moderna and NIH, 3rd mRNA Covid vaccine player CureVac now partners with fellow German company Bayer Pharmaceuticals, to accelerate clinical, regulatory and supply. Increased collaboration across the industry will be another major positive impact of Covid-19 crisis. #postcovid19 #vaccinessavelives #innovation #launches Continue reading

Oxford University/AstraZeneca Covid-19 vaccine, based on viral vector technology and now approved by UK authorities, will be vital for developing countries. Compared to mRNA based vaccines, it is cheaper to make and can be stored at standard refrigeration temperature, making it easier to use in poorer and harder-to-reach parts of the world. Fantastic achievement ! #postcovid19 #innovation #launch #vaccinessavelives Continue reading

Infectious diseases have been largely forgotten by Pharma R&D and investors, as chronic diseases, cancer and rare diseases gave better short term ROI thanks to continuous treatment or higher prices. However, the Covid-19 pandemic has shed new light on the critical importance of fighting and preventing infections, both viral and bacterial, not mentioning growing concern about antibiotic resistance. Beyond the incredible effort that led to the development of several successful

Wound closure could be revolutionized with strong double-side adhesive created by MIT engineers. Contrary to existing adhesives or sealants, the product can be stuck and unstuck on internal wounds without tissue damage, giving great perspectives to surgeons. #woundcare #innovation Continue reading